Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07313592 · ClinicalTrials.gov registry record
Whole Genome Sequencing (ChromoSeq®) for Acute Lymphoblastic Leukemia (ALL) Patients
A clinical trial, sponsored by Washington University School of Medicine.
- Recruiting
- Registry status
- 60
- Enrollment target
NCT07313592 is a clinical trial that is actively recruiting participants, run by Washington University School of Medicine. The registered enrollment target is 60 participants.
The verdict
NCT07313592 is actively recruiting participants, sponsored by Washington University School of Medicine.
- RECRUITING
- Registry status
- 60 participants
- Enrollment target
Study Summary
This is a prospective specimen collection study evaluating the feasibility of using the ChromoSeq® assay for upfront classification in a real-time clinical setting of pediatric and young adult acute lymphoid leukemia (ALL) patients. Sixty patients will undergo collections of bone marrow and/or peripheral blood for the ChromoSeq® assay at time of initial workup, and the patients will then be followed for clinical outcomes for up to 65 months.
Interventions
- DEVICE ChromoSeq® assay testing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2026-06-03 |
| Est. Completion | 2028-07-15 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07313592
The ClinicalTrials.gov registry entry for NCT07313592 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ChromoSeq® assay testing is the first listed.
NCT07313592 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07313592 about?
NCT07313592 is a clinical study titled "Whole Genome Sequencing (ChromoSeq®) for Acute Lymphoblastic Leukemia (ALL) Patients". This is a prospective specimen collection study evaluating the feasibility of using the ChromoSeq® assay for upfront classification in a real-time clinical setting of pediatric and young adult acute lymphoid leukemia (ALL) patients. Sixty patients will undergo collections of bone marrow and/or perip...
What is the current status of trial NCT07313592?
This trial is currently recruiting. The enrollment target is 60 participants. The study started on 2026-06-03. Estimated completion is 2028-07-15.
What interventions are being tested in trial NCT07313592?
The interventions under investigation include: ChromoSeq® assay testing (DEVICE).
Who is sponsoring clinical trial NCT07313592?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.